Candel Therapeutics reported earnings of -$ 0.28 per CADL share on Nov 13, 2026, falling short of analysts' expectations by
| Report Date | Nov 13, 2026 |
|---|---|
| Forecasted EPS | -$ 0.34 |
| Earnings Per Share (Surprise) | -$ 0.28 (+$ 0.05719) |
| Last Year's EPS | -$ 0.18 |
| EPS YoY Change |
Out of the last 27 earnings reporting periods, Candel Therapeutics beat analysts’ expectations 9 times and fell short of expectations 10 time(s). Candel Therapeutics reported earnings per share of -$ 0.28 in the last report surpassing an estimated EPS of -$ 0.34 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 0.34 | -$ 0.28 | -$ 0.21 | |
| Aug 13, 2026 | -$ 0.24 | -$ 0.52 | -$ 0.09 | |
| May 14, 2026 | -$ 0.22 | -$ 0.14 | $ 0.13 | |
| Mar 12, 2026 | -$ 0.24 | -$ 0.54 | -$ 0.40 | |
| Nov 13, 2025 | -$ 0.17 | -$ 0.21 | -$ 0.33 | |
| Aug 14, 2025 | -$ 0.17 | -$ 0.09 | -$ 0.74 | |
| May 13, 2025 | -$ 0.24 | $ 0.13 | -$ 0.28 | |
| Mar 13, 2025 | -$ 0.23 | -$ 0.40 | -$ 0.38 | |
| Nov 14, 2024 | - | -$ 0.33 | -$ 0.29 | |
| Aug 13, 2024 | - | -$ 0.74 | -$ 0.33 | |
| May 14, 2024 | - | -$ 0.28 | -$ 0.30 | |
| Mar 28, 2024 | -$ 0.16 | -$ 0.38 | -$ 0.18 | |
| Nov 9, 2023 | -$ 0.19 | -$ 0.29 | -$ 0.30 | |
| Aug 10, 2023 | -$ 0.23 | -$ 0.33 | -$ 0.14 | |
| May 11, 2023 | -$ 0.35 | -$ 0.30 | -$ 0.03 | |
| Mar 30, 2023 | -$ 0.16 | -$ 0.18 | $ 0.05 | |
| Nov 10, 2022 | -$ 0.53 | -$ 0.30 | -$ 0.34 | |
| Aug 5, 2022 | -$ 0.54 | -$ 0.14 | -$ 0.31 | |
| May 12, 2022 | -$ 0.49 | -$ 0.03 | -$ 0.24 | |
| Mar 29, 2022 | -$ 0.32 | $ 0.05 | -$ 0.56 |
Candel Therapeutics’s stock was trading at $ 8.39 on Nov 12, 2026 a day before the last earnings report was released.
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 13, 2026 | -$ 0.28 | $ 8.39 | ||
| Aug 13, 2026 | -$ 0.52 | $ 10.68 | $ 11.72 | |
| May 14, 2026 | -$ 0.14 | $ 8.94 | $ 8.77 | |
| Mar 12, 2026 | -$ 0.54 | $ 5.10 | $ 4.67 | |
| Nov 13, 2025 | -$ 0.21 | $ 4.92 | $ 4.64 | |
| Aug 14, 2025 | -$ 0.09 | $ 6.40 | $ 6.09 | |
| May 13, 2025 | $ 0.13 | $ 5.01 | $ 5.34 | |
| Mar 13, 2025 | -$ 0.40 | $ 8.09 | $ 8.75 | |
| Nov 14, 2024 | -$ 0.33 | $ 4.29 | $ 3.80 | |
| Aug 13, 2024 | -$ 0.74 | $ 5.58 | $ 5.26 | |
| May 14, 2024 | -$ 0.28 | $ 10.20 | $ 14.00 | |
| Mar 28, 2024 | -$ 0.38 | $ 1.54 | $ 1.75 | |
| Nov 9, 2023 | -$ 0.29 | $ 1.00 | $ 0.903 | |
| Aug 10, 2023 | -$ 0.33 | $ 1.10 | $ 1.15 | |
| May 11, 2023 | -$ 0.30 | $ 1.78 | $ 1.55 | |
| Mar 30, 2023 | -$ 0.18 | $ 1.41 | $ 1.35 | |
| Nov 10, 2022 | -$ 0.30 | $ 1.50 | $ 1.62 | |
| Aug 5, 2022 | -$ 0.14 | $ 3.45 | $ 3.38 | |
| May 12, 2022 | -$ 0.03 | $ 3.67 | $ 4.00 | |
| Mar 29, 2022 | $ 0.05 | $ 4.54 | $ 4.59 |
Candel Therapeutics released its most recent earnings reports in November 2026, August 2026, May 2026, March 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Candel Therapeutics beat analysts’ expectations during the last earnings period by
